Why the ResMed (ASX:RMD) share price just hit an all-time high

A confluence of factors are pushing its share price higher.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc.(ASX: RMD) share price is breaking new records.

At the time of writing, shares in the healthcare company are trading for $35.28 – up 0.54%. At one point, shares reached an intraday and all-time high of $35.44.

The S&P/ASX 200 Index (ASX: XJO) is also having a record day. Presently, the benchmark index is 0.05% higher but reached a high of 7,417.6 points. While the influence of the general market on the ResMed share price could be having an effect, there may be more to the story.

Let's take a closer look.

four excited doctors with their hands in the air

Image source: Getty Images

Healthcare shares are looking fit

Throughout July, ASX healthcare shares, like ResMed, have been surging. Just in the last month, the ResMed share price has jumped 8.1%, Sonic Healthcare Limited (ASX: SHL) improved 8.2% and CSL Limited (ASX: CSL) shares are up 1.5%.

With COVID back in the spotlight, as the delta variant causes a sharp increase in cases across the world, healthcare shares – including ResMed – may be the few to benefit from this strain of the virus.

Experts too have had nothing but positive words to say about the ResMed share price in recent days.

Analysts at Macquarie Group, for example, say ResMed is a growth share for investors to buy right now. Randal Jenneke, head of Australian equities at T Rowe Price Group, says ResMed is a "quality" share for investors.

Jenneke previously said

Over more than two decades of data for the Australian market, high quality had outperformed low quality by 6.7% per annum.

… [quality shares like ResMed are] poised to outperform over the coming year.

As the ResMed share price has just hit a 52-week high, this advice is being borne out – at least for the time being.

Another factor potentially helping ResMed shares – the falling Aussie dollar.

Experts are tipping it to fall below 70 cents against the greenback. For ASX listed companies that predominately do business in the US, this could be a windfall.

ResMed is one of those companies that predominantly trade in the US. In fact, it is a dual listed company with shares on the New York Stock Exchange.

ResMed share price snapshot

Over the past 12 months, the ResMed share price has increased 23.1%. Year-to-date it is up an even greater 28.3%.

ResMed has a market capitalisation of around $51 billion.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear cuts FY26 earnings outlook amid softer sales

Cochlear reduces its FY26 earnings guidance amid softer implant sales, ongoing challenges in key markets, and a focus on long-term…

Read more »

A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
Healthcare Shares

EBOS Group trims FY26 earnings guidance as fuel costs bite

EBOS Group trims FY26 earnings guidance as elevated fuel costs weigh on its healthcare distribution businesses.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Share Market News

Up 68% from a multi-year low. Are Telix shares a buy, sell or hold?

Telix shares crashed to just $8.63 per share in mid-February.

Read more »

Health professional working on his laptop.
Broker Notes

Are Orthocell shares a buy after crashing 7% yesterday?

These healthcare shares could be on discount right now.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares I think can beat the market

Healthcare trends like ageing populations and rising demand can create long-term opportunities.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up 2,000% in a year, why this ASX healthcare stock is in focus today

4DMedical shares rise as multiple updates land across key markets.

Read more »